8-KEarnings & ResultsOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Dec 24, 2009)

Filed December 24, 2009For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on December 24, 2009, reporting the completion of a significant strategic transaction. The company finalized the split-off of its 83.1% ownership in Mead Johnson Nutrition Company. This was executed through an exchange offer where shareholders tendered BMY shares in exchange for shares of Mead Johnson. The exchange offer was oversubscribed, indicating strong shareholder interest. Concurrently, BMY also updated its full-year 2009 earnings per share (EPS) guidance from continuing operations. The filing includes press releases detailing the Mead Johnson divestiture and the EPS guidance update, along with pro forma financial information reflecting these events.

Key Highlights

  • 1Completion of the Mead Johnson Nutrition Company split-off, reducing BMY's stake to effectively zero.
  • 2The split-off was achieved through a shareholder exchange offer, which was oversubscribed.
  • 3BMY's ownership in Mead Johnson was 83.1% prior to the transaction.
  • 4The company updated its full-year 2009 earnings per share (EPS) guidance from continuing operations.
  • 5Unaudited pro forma financial information related to these events is included.
  • 6The transaction signifies a strategic shift for BMY, focusing on its core pharmaceutical business.

Frequently Asked Questions

The primary purpose was to report the completion of the split-off of Bristol-Myers Squibb's ownership in Mead Johnson Nutrition Company and to update the company's full-year 2009 earnings per share guidance.

A split-off is a transaction where a company offers its shareholders the opportunity to exchange their shares of the parent company for shares of a subsidiary. In this case, BMY shareholders exchanged their BMY shares for shares of Mead Johnson Nutrition Company.

The filing indicates the exchange offer was oversubscribed, suggesting significant shareholder interest and potentially a favorable reception to shedding the nutrition business. The updated EPS guidance will provide further context on the financial impact.

The updated EPS guidance provides investors with revised expectations for the company's profitability from its continuing operations for the full year 2009. Investors should review the accompanying press release (Exhibit 99.2) for the specific guidance figures and rationale.